April 10, 2020 -- ReForm Biologics has received a U.S. patent for therapeutic protein formulations that reduce protein aggregation and stabilize proteins during storage.
The formulations include a new class of stabilizers to serve as an alternative to traditional surfactants. The company has licensed its ReForm excipients used in biotherapeutic formulations to MilliporeSigma.
ReForm also announced its first patent in Japan for technology to reduce the viscosity of highly concentrated antibody solutions. The excipient technology will enable scientists to more effectively formulate solutions for more preferable delivery routes, the company noted.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
